Publication details
Cílená terapie chronické myeloidní leukemie
| Title in English | Targeted therapy for chronic myeloid leukaemia |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| web | https://www.actamedicinae.cz/literatura/AM_112023_literatura.pdf |
| Keywords | chronic myeloid leukemia; tyrosine kinase inhibitors; asciminib; remission without the need for therapy |
| Attached files | |
| Description | The introduction of imatinib, the first tyrosine kinase inhibitor targeting the BCR::ABL1 kinase, into routine clinical practice in recent dasatinib, nilotinib, bosutinib, ponatinib and asciminib have been introduced in the past 20 years, the latest addition to the chronic myeloid leukaemia portfolio, and the only allosteric inhibitor Tyrosine kinase BCR::ABL1. goals of extending the life expectancy of patients with newly diagnosed disease to that of their healthy peers. However, this raises new challenges in terms of achieving remission without the need for therapy, not only in trials but also in routine clinical practice or improving the prognosis of patients in advanced stages of the disease. A look at current targeted therapies for chronic myeloid leukemia in the context of its discontinuation and subsequent remission without the need for therapy is offered in the present paper. |
| Related projects: |